Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

The New England Journal of Medicine

- PMLiVE

Longitude Prize on Dementia launches innovator hackathons to those aiming for £1m grand prize

The prize will award a total of £4.34m for technology-based tool for people living with dementia

- PMLiVE

Biogen doses first patient with litifilimab in cutaneous lupus erythematosus study

The phase 2/3 study is expected to be conducted at approximately 238 sites worldwide

- PMLiVE

Biogen and Denali dose first patients with LRRK2 inhibitor in Parkinson’s disease study

Mutations in the LRRK2 gene are one of the most common causes of familial Parkinson’s disease

- PMLiVE

Biogen and Eisai’s lecanemab shows promise in confirmatory Alzheimer’s study

Results from the phase 3 trial showed reduction in clinical decline

Biogen Idec building

Biogen to pay $900m to settle whistleblower’s MS drug kickback lawsuit

For pursuing the case, the former employee will receive about $250m

- PMLiVE

Biogen’s tofersen shows promise in rare form of ALS in new data analysis

Mutations in the SOD1 gene are responsible for approximately 2% of global ALS cases

- PMLiVE

Tiziana announces Brigham and Women’s hospital will receive ALS Association grant

ALS affects as many as 30,000 people in the US

- PMLiVE

Neuron23 and QIAGEN partner to develop companion diagnostic for Parkinson’s disease

No laboratory tests are currently available for diagnosing the disease in non-genetic cases

- PMLiVE

FDA and NIHR launch public-private partnership for rare neurodegenerative diseases

The announcement follows President Biden signing the Accelerating Access to Critical Therapies for ALS Act in December 2021

- PMLiVE

CuraSen Therapeutics doses first patients with novel combination therapy in dementia study

CuraSen Therapeutics doses first patients with novel combination therapy in dementia study

- PMLiVE

Biogen and Eisai share latest lecanemab results for the treatment of Alzheimer’s disease

Eisai presented the data at the Alzheimer’s Association International Conference (AAIC)

- PMLiVE

Positive results for Biogen’s lupus drug published in NEJM

Around 90% of people with lupus are women, a condition for which there is currently no cure

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links